SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Dybedal Ingunn) ;lar1:(liu)"

Sökning: WFRF:(Dybedal Ingunn) > Linköpings universitet

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Baliakas, Panagiotis, 1977-, et al. (författare)
  • Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
  • 2019
  • Ingår i: HemaSphere. - : LIPPINCOTT WILLIAMS & WILKINS. - 2572-9241. ; 3:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased risk for the development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting the diagnosis of MN with germline predisposition is of crucial clinical significance since it may tailor therapy, dictate the selection of donor for allogeneic hematopoietic stem cell transplantation (allo-HSCT), determine the conditioning regimen, enable relevant prophylactic measures and early intervention or contribute to avoid unnecessary or even harmful medication. Finally, it allows for genetic counseling and follow-up of at-risk family members. Identification of these patients in the clinical setting is challenging, as there is no consensus due to lack of evidence regarding the criteria defining the patients who should be tested for these conditions. In addition, even in cases with a strong suspicion of a MN with germline predisposition, no standard diagnostic algorithm is available. We present the first version of the Nordic recommendations for diagnostics, surveillance and management including considerations for allo-HSCT for patients and carriers of a germline mutation predisposing to the development of MNs.
  •  
2.
  • Egg, David, et al. (författare)
  • Therapeutic options for CTLA-4 insufficiency
  • 2022
  • Ingår i: Journal of Allergy and Clinical Immunology. - : MOSBY-ELSEVIER. - 0091-6749 .- 1097-6825. ; 149:2, s. 736-746
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Heterozygous germline mutations in cytotoxic T lymphocyte-associated antigen-4 (CTLA4) impair the immunomodulatory function of regulatory T cells. Affected individuals are prone to life-threatening autoimmune and lymphoproliferative complications. A number of therapeutic options are currently being used with variable effectiveness. Objective: Our aim was to characterize the responsiveness of patients with CTLA-4 insufficiency to specific therapies and provide recommendations for the diagnostic workup and therapy at an organ-specific level. Methods: Clinical features, laboratory findings, and response to treatment were reviewed retrospectively in an international cohort of 173 carriers of CTLA4 mutation. Patients were followed between 2014 and 2020 for a total of 2624 months from diagnosis. Clinical manifestations were grouped on the basis of organ-specific involvement. Medication use and response were recorded and evaluated. Results: Among the 173 CTLA4 mutation carriers, 123 (71%) had been treated for immune complications. Abatacept, rituximab, sirolimus, and corticosteroids ameliorated disease severity, especially in cases of cytopenias and lymphocytic organ infiltration of the gut, lungs, and central nervous system. Immunoglobulin replacement was effective in prevention of infection. Only 4 of 16 patients (25%) with cytopenia who underwent splenectomy had a sustained clinical response. Cure was achieved with stem cell transplantation in 13 of 18 patients (72%). As a result of the aforementioned methods, organ-specific treatment pathways were developed. Conclusion: Systemic immunosuppressants and abatacept may provide partial control but require ongoing administration. Allogeneic hematopoietic stem cell transplantation offers a possible cure for patients with CTLA-4 insufficiency.
  •  
3.
  •  
4.
  •  
5.
  • Wedge, Eileen, et al. (författare)
  • Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia : Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
  • 2021
  • Ingår i: Transplantation and Cellular Therapy. - : Elsevier. - 2666-6375 .- 2666-6367. ; 27:12, s. 991.e1-991.e9
  • Tidskriftsartikel (refereegranskat)abstract
    • Chronic myelomonocytic leukemia (CMML) is an aggressive disease in which survival after allogeneic hematopoietic stem cell transplantation (HCT) remains relatively poor. An assessment of prognostic factors is an important part of treatment decision making and has the potential to be greatly improved by the inclusion of molecular genetics. However, there is a significant knowledge gap in the interpretation of mutational patterns. This study aimed to describe outcomes of allogeneic HCT in patients with CMML in relation to clinical and molecular genetic risk factors. This retrospective study included 64 patients with CMML who underwent allogeneic HCT between 2008 and 2018, with a median follow-up of 5.4 years. Next-generation sequencing using targeted myeloid panels was carried out on saved material from 51 patients from the time of transplantation. Kaplan-Meier and Cox regression were used for analysis of overall survival (OS), and cumulative incidence with competing risks and Fine and Gray models were used for analysis of relapse and nonrelapse mortality (NRM). Mutations were detected in 48 patients (94%), indicating high levels of minimal residual disease (MRD) positivity at transplantation, even among those in complete remission (CR) (n = 14), 86% of whom had detectable mutations. The most frequently mutated genes were ASXL1 (37%), TET2 (37%), RUNX1 (33%), SRSF2 (26%), and NRAS (20%). Risk stratification using the CMML-specific Prognostic Scoring System molecular score (CPSS-Mol) resulted in 45% of patients moving to a higher risk-group compared with risk stratification using the CPSS. High leucocyte count (>= 13 x 10(9)/L), transfusion requirement, and previous intensive chemotherapy were associated with higher incidence of relapse. Being in CR was not linked to better outcomes. Neither ASXL1 nor RUNX1 mutation was associated with a difference in OS, relapse, or NRM, despite being high risk in the nontransplantation setting. TET2 mutations were associated with a significantly higher 3-year OS (73% versus 40%; P =.039). Achieving MRD-negative CR was rare in this CMML cohort, which may explain why we did not observe better outcomes for those in CR. This merits further investigation. Our analyses suggest that the negative impact of ASXL1 and RUNX1 mutations can be overcome by allogeneic HCT; however, risk stratification is complex in CMML and requires larger cohorts and multivariate models, presenting an ongoing challenge in this rare disease.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5
Typ av publikation
tidskriftsartikel (3)
konferensbidrag (2)
Typ av innehåll
refereegranskat (5)
Författare/redaktör
Dybedal, Ingunn (5)
Hovland, Randi (3)
Josefsen, Dag (2)
Malm, Claes (2)
Fioretos, Thoas (2)
Ljungman, Per (2)
visa fler...
Olofsson, Tor (2)
Simonsson, Bengt (2)
Gronbaek, Kirsten (2)
Barbany, Gisela (2)
Lassen, Carin (2)
Richter, Johan (2)
Porkka, Kimmo (2)
Mustjoki, Satu (2)
Hjorth-Hansen, Henri ... (2)
Weiss-Bjerrum, Ole (2)
Friis, Lone Smidstru ... (2)
Kittang, Astrid Olsn ... (2)
Ohm, Lotta (2)
Hellström-Lindberg, ... (1)
Nilsson, Lars (1)
Ejerblad, Elisabeth (1)
Jahnukainen, Kirsi (1)
Ungerstedt, Johanna (1)
Werlenius, Olle (1)
Albert, Michael H (1)
Imai, Kohsuke (1)
Morio, Tomohiro (1)
Papaemmanuil, Elli (1)
Baliakas, Panagiotis ... (1)
Marquart, Hanne Vibe ... (1)
Andersen, Mette K. (1)
Schmidt, Reinhold (1)
Ehrencrona, Hans (1)
Lorenz, Fryderyk (1)
Moutschen, Michel (1)
Bakhtiar, Shahrzad (1)
Tesi, Bianca (1)
Andersen, Mette Klar ... (1)
Creignou, Maria (1)
Raaschou-Jensen, Kla ... (1)
Kilpivaara, Outi (1)
Wartiovaara-Kautto, ... (1)
Stray-Pedersen, Asbj ... (1)
Rustad, Cecilie F. (1)
Lautrup, Charlotte K ... (1)
Cammenga, Jörg, 1969 ... (1)
Hellstrom-Lindberg, ... (1)
Antunovic, Petar (1)
Jädersten, Martin (1)
visa färre...
Lärosäte
Karolinska Institutet (3)
Uppsala universitet (2)
Lunds universitet (1)
Språk
Engelska (5)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy